Liraglutide mimics the natural GLP-1 hormone, which slows gastric emptying, reduces appetite, and enhances feelings of fullness
For labeling, use a lab printer such as NIIMBOT
The addition of GIP receptor activation may help mitigate some gastrointestinal side effects
adult obesity prevalence reached 40.3% during 2021-2023, with 23 states reporting adult obesity rates above 35% in 2023
While the FDAs Food, Drug, and Cosmetic Act allows it to turn a blind eye to pharmacists producing and selling non-approved compounded versions under certain circumstances, this practice has led to a billion-dollar shadow industry of compounded GLP-1 drugs
All information presented on this website is offered for educational and scientific reference only